Lipidomics Biomarkers: A Blood Panel for Alzheimer's
- Jul 27
- 4 min read
```html
Blood tests for Alzheimer's disease still lean on amyloid and tau, yet lipid changes surface in neurons long before plaques dominate a scan. A team at China Pharmaceutical University went after that gap. They profiled 156 people spanning normal cognition, amnestic mild cognitive impairment, and Alzheimer's, then built lipidomics biomarkers from two blood compartments at once: plasma and the red blood cell membrane. The payoff is a six-lipid panel that told patients from healthy controls apart with an AUC of 0.933.
Key Takeaways
Red blood cell membranes captured more Alzheimer's-linked lipid changes than plasma, so the sampling matrix matters as much as the instrument in any lipidomics workflow.
A six-lipid panel drawn from these lipidomics biomarkers separated Alzheimer's patients from cognitively normal adults with an AUC of 0.933.
Sphingomyelin and ceramide shifts tracked disease severity, pointing to membrane lipid metabolism as an early readout rather than a late casualty.
This is a discovery-stage result in 156 participants; the panel needs replication in an independent cohort before anyone reaches for it clinically.
How Blood Lipidomics Biomarkers Read Alzheimer's Progression
The group ran untargeted lipid profiling on a Waters ACQUITY UPLC coupled to a Xevo G2-XS Q-TOF, pulling lipids from both plasma and washed red cell membranes. That dual-matrix design is the interesting call. Plasma reflects circulating lipid transport, while the erythrocyte membrane is a slow-turnover structural reservoir that can register chronic remodeling a single plasma draw would miss. Across both matrices the authors annotated 448 lipids from 14 classes, then narrowed to 138 species that differed by disease group.
Key Findings
A tight panel. Six species carried most of the signal: TAG 50:1, PC 34:2e, SM(d20:0/24:1), SM d35:2, PE 36:4, and CE 22:6.
Membrane beat plasma. Red cell membranes showed 84 down-regulated and 17 up-regulated lipids, versus 21 down and 17 up in plasma.
Staging held at the extremes. Group AUCs reached 0.933 for normal versus Alzheimer's and 0.859 for normal versus mild cognitive impairment, but only 0.677 between the two disease stages.
Phospholipid loss stood out. Lower phosphatidylcholine and phosphatidylethanolamine signaled membrane breakdown, while sphingomyelin dysregulation scaled with pathology.
Figure 1. Lipid extraction optimization for plasma and red blood cell membranes. (A) Number of lipids recovered by four sample preparation methods; (B) total ion chromatograms showing separation under the selected isopropanol-based method; (C) Venn diagrams comparing lipid coverage across ion modes and between the two blood matrices. Adapted from He et al. (2025), Alzheimer's Research and Therapy.
Why the Red Cell Membrane Earns Its Place
Most blood lipidomics defaults to plasma or serum because it banks easily, yet this paper argues the erythrocyte membrane deserves a seat too. Its lipids turn over on the timescale of the cell's 120-day lifespan, so the membrane lipidome reads like a running average of metabolic state rather than a snapshot. Work from Han and colleagues (2016) made a similar case for membrane-focused lipid profiling in neurodegeneration.
What a Six-Lipid Panel Can and Cannot Do
The panel's strength sits at the ends of the cognitive spectrum, where it cleanly split healthy from diseased. Its weakness is the clinically hard question: telling mild cognitive impairment from established Alzheimer's, where the AUC slid to 0.677. Read this as a confirmatory step toward a blood lipid panel, not a finished diagnostic.
Choosing the Sampling Matrix Before the Method
The dual-matrix result lands because red cell membranes and plasma answer different questions, and pulling both from one draw hinges on extraction chemistry that survives the membrane wash steps. We run this kind of paired lipid profiling in-house, and our experience with clinical lipidomics services at Dalton echoes the finding that the erythrocyte membrane often carries the cleaner signal. Pairing membrane and plasma lipids early is the kind of choice that shapes a downstream multi-omics biomarker discovery program, so we treat matrix selection as a first-class design decision.
Frequently Asked Questions
What are lipidomics biomarkers?
Lipidomics biomarkers are specific lipid molecules, such as ceramides or phosphatidylcholines, whose measured levels track a disease state. They come from lipid profiling of blood or tissue, usually by mass spectrometry. A useful panel shifts reproducibly with the condition and stays cheap enough to measure routinely.
Can lipidomics biomarkers detect Alzheimer's disease?
In this study a six-lipid panel from plasma and red blood cell membranes separated Alzheimer's patients from cognitively normal adults with an AUC of 0.933. Accuracy dropped when distinguishing mild cognitive impairment from Alzheimer's. The panel is promising but needs validation in a larger, independent cohort.
How much sample does a blood lipidomics panel need?
A typical LC-MS lipidomics workflow needs only microliters of plasma or a small red cell pellet, well within a standard clinical blood draw. The main cost drivers are sample preparation, instrument time, and the data processing behind lipid identification. Running both fractions from one draw keeps the per-sample cost manageable.
Conclusion
What is believable now: erythrocyte membrane lipids carry a real, measurable Alzheimer's signal, and sampling two blood compartments beats leaning on plasma alone. What isn't settled is whether a six-lipid panel trained on 156 people holds up across sites, ages, and comorbidities. For groups designing early-detection studies, the practical move is to bank a red cell fraction next to plasma so the membrane lipidome stays on the table.
Related Reading
See how we run these analyses in one lab: Dalton's multi-omics CRO services.
Citation
He, D., Bao, Y., Yuan, S., Wang, Y., Cai, J., Xu, F., Chang, T., Zhang, P., Yue, M., Pan, X., Hao, H., and Zheng, Q. (2025). Integrated plasma and red blood cell membrane lipidomics analysis unveils novel biomarker panel for Alzheimer's disease. Alzheimer's Research and Therapy, 17(1). https://doi.org/10.1186/s13195-025-01830-7
Note
This blog post summarizes findings from the above-cited research. Figures are adapted from the original publication. For full details, please refer to the source article.
By Seungjun Yeo, CEO at Dalton Bioanalytics. Specializing in multi-omics mass spectrometry for drug discovery and biomarker research.
```